EnPlusOne Biosciences Aims to Revolutionize RNA Therapeutics with Enzymatic Synthesis
August 5th, 2025 4:00 PM
By: Newsworthy Staff
EnPlusOne Biosciences, under the leadership of CEO Clare Murray Ph.D., is pioneering enzymatic synthesis to overcome the limitations of current RNA manufacturing methods, promising a future of scalable, pure, and environmentally friendly RNA therapeutics.
EnPlusOne Biosciences, a biotechnology company based in Watertown, MA, is making strides in the RNA therapeutics market with its innovative enzymatic synthesis technology. The company's mission, as articulated by CEO Clare Murray Ph.D., is to enable the synthesis of pure and precise RNA for therapeutic use at an unprecedented scale. This advancement is critical as the demand for RNA therapeutics, including siRNA, ASOs, mRNA, and gRNA for CRISPR, continues to grow amidst challenges posed by current manufacturing methods.
The current standard for RNA manufacturing, phosphoramidite chemistry, is fraught with limitations. It cannot produce siRNA at the needed levels or gRNA with the required purity, and it relies on nonrenewable resources and harsh chemicals. EnPlusOne's solution lies in mimicking nature's method of RNA synthesis, utilizing enzymes in water to produce RNA with high fidelity and sustainability. Their ezRNA platform not only addresses the immediate needs of genetic medicine developers but also opens new avenues for discovering innovative RNA therapeutics.
Dr. Murray's vision for EnPlusOne includes near-term goals such as developing collaborations with partners in the RNA therapeutics space and achieving operational improvements as the company scales. The proprietary technology behind EnPlusOne's advances combines the best of biology and chemistry, offering a cleaner, more precise method of RNA synthesis. This approach has the potential to revolutionize the life sciences industry by enabling drug developers to deliver on the promise of RNA therapeutics to patients worldwide.
Looking ahead, EnPlusOne is focused on embedding its proprietary technology in the first-generation RNA therapeutics being developed today. The company is also exploring novel modifications and delivery technologies to expand the range of diseases that can be treated with RNA therapeutics. Upcoming milestones include closing new partnerships and participating in leading conferences such as the 2025 Nature Conference and the Oligonucleotide Therapeutics Society conference, signaling EnPlusOne's commitment to advancing the field of RNA therapeutics.
Source Statement
This news article relied primarily on a press release disributed by citybiz. You can read the source press release here,
